Evaluation of the tolerability and safety of [²²⁵Ac]Ac-PSMA-I&T in patients with metastatic prostate cancer: a phase I dose escalation study.

ABSTRACT:

Background

Life expectancy of patients with metastatic castration-resistant prostate cancer (mCRPC) is still limited despite several systemic treatments. Within five years after diagnosis of primary prostate cancer, 10-20% of the patients have mCRPC and curation is not an option. Radionuclide therapy (RNT) targeted against prostate-specific membrane antigen (PSMA) emerged as a new treatment option and showed effective results in patients with mCRPC. Survival benefit after [¹⁷⁷Lu]Lu-PSMA RNT has already been demonstrated in several clinical trials. However, [²²⁵Ac]Ac-PSMA (²²⁵Ac-PSMA) appears to be an even more promising radiopharmaceutical for the treatment of mCRPC. The use of alpha emitting radionuclides offers advantages over beta emitting radion

SUBMITTER: Ling SW 

PROVIDER: S-EPMC10826262 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature